Imbiorey Completes 230 Million RMB Series A Financing, with T-Capital as Financial Advisor for Two Consecutive Rounds
On February 22, 2022, Imbiorey (Hangzhou) Biomedicine Co., Ltd. announced the completion of a 230 million RMB Series A financing. T-Capital served as the financial advisor for two consecutive rounds of financing for Imbiorey, participating in the company’s 2020 Pre-A and this Series A round.
This round of financing was co-led by Rui enjoy yuan Fund and Zhongnan Venture Capital Fund, with participation from several investment institutions including Longmen Capital, Zhongguancun Kaiyuan Capital, Dongfang Huisheng, and Beiyu Bairui Fund.
Previously, Imbiorey completed an 80 million RMB Pre-A round of financing invested by Longpan Fund in 2020. After the completion of this Series A round, Imbiorey’s total financing amount has reached 310 million RMB.
This round of financing will be mainly used to advance Imbiorey’s innovative off-the-shelf allogeneic CAR-NK and NK cell therapy drugs into the clinical stage, while supporting IND-enabling studies, GMP plant construction, talent team building, external business cooperation, and company operations.
Transaction Overview
| Item | Information |
|---|---|
| Client | Imbiorey (Hangzhou) Biomedicine Co., Ltd. |
| Transaction Type | Equity Financing |
| Financing Round | Series A |
| Financing Amount | 230 Million RMB |
| Financing Date | February 22, 2022 |
| Industry | Biopharmaceuticals / Cell Therapy |
| Core Field | CAR-NK, NK Cell Therapy |
| Lead Investors | Rui enjoy yuan Fund, Zhongnan Venture Capital Fund |
| Follow-on Investors | Longmen Capital, Zhongguancun Kaiyuan Capital, Dongfang Huisheng, Beiyu Bairui Fund, etc. |
| Previous Financing | 2020 Pre-A Round, 80 Million RMB |
| Total Financing | 310 Million RMB |
| T-Capital’s Role | Financial advisor for two consecutive rounds |
T-Capital Serves as Financial Advisor for Two Consecutive Rounds of Financing for Imbiorey
Imbiorey’s cooperation with T-Capital is not a one-time financing project.
T-Capital has served as the financial advisor for Imbiorey’s 2020 Pre-A and 2022 Series A rounds of financing.
In 2020, Imbiorey completed an 80 million RMB Pre-A round of financing invested by Longpan Fund.
In 2022, Imbiorey further completed a 230 million RMB Series A financing, co-led by Rui enjoy yuan Fund and Zhongnan Venture Capital Fund, with the participation of several professional investment institutions.
The cumulative financing amount for the two rounds reached:
310 million RMB
For innovative drug and cell therapy companies, moving from early-stage financing to the clinical stage usually requires continuous R&D investment and long-term capital support.
T-Capital’s continuous participation in Imbiorey’s financing at different stages of development also reflects T-Capital’s service model of long-term service to healthcare innovation companies and continuous connection of companies with professional capital resources.
Imbiorey: Focusing on Innovative Off-the-Shelf CAR-NK and NK Cell Therapy
Founded in 2014, Imbiorey focuses on the treatment of tumors and immune diseases.
In 2016, the company began to focus on the development of innovative universal off-the-shelf CAR-NK cell therapies and has developed a series of cell and antibody drugs based on its original technology platform.
The company is committed to addressing unmet clinical needs, with multiple product pipelines advancing clinical development simultaneously.
This round of financing focuses on supporting Imbiorey’s unique:
- Non-gene-modified CAR-raNK® cell therapy;
- tiNK® cell therapy;
- NK Cell Engager cell therapy.
Among them, the off-the-shelf CAR-raNK® cell therapy drug candidates IBR733 and IBR854 are planned to be further advanced to the clinical stage.
This Round of Financing Will Be Used to Promote Multiple R&D and Industrialization Directions
According to the company’s disclosure, this 230 million RMB financing will be mainly used for the following aspects.
1. Advancing Core Cell Therapy Drug Candidates to Clinical Stage
The financing will support the advancement of off-the-shelf CAR-raNK® cell therapy drug candidates such as IBR733 and IBR854 to the clinical stage.
2. Promoting IND-enabling Studies
The funds will support IND-enabling studies for multiple tiNK® and NK Cell Engager cell therapy drug candidates.
3. Building a New GMP Plant
The company plans to build a new GMP plant to provide production capacity support for subsequent cell therapy product R&D and industrialization.
4. Building a Talent Team
The financing will be used to further strengthen the construction of talent in innovative drug R&D, clinical translation, and industrialization.
5. Strengthening External Business Cooperation
The company plans to use this round of financing to further strengthen external business cooperation and promote the connection between technology, products, and industrial resources.
6. Supplementing Company’s Working Capital
The financing is also used to support the company’s daily operations and continuous development.
Professional Team is an Important Foundation for Imbiorey’s Innovative Drug R&D
Imbiorey’s core team has more than 20 years of research and industrial experience in innovative drug R&D and clinical translation.
Company founder and CEO Dr. Zhenwei Miao has many years of industrial drug R&D experience, having held important positions in several Nasdaq-listed companies, and served as Chief Scientist at Enanta, Senior Director of Chemistry at Ambrx, and Chief Technology Officer at Sorrento.
Dr. Miao has participated in advancing multiple products into clinical trials and bringing them to market.
Imbiorey’s Chief Medical Officer, Dr. Shizhou Liu, has a background in clinical R&D and drug development, having conducted research at Harvard University’s Massachusetts General Hospital, the Danish Cancer Society, and the Royal Academy of Engineering in the UK. He also served as a dual-appointed PI at the Translational Medicine Institute of Zhejiang University and the First Affiliated Hospital of Zhejiang University.
Dr. Liu has also participated in and led the clinical development of multiple drugs at Boehringer Ingelheim, Johnson & Johnson, and Crown Bioscience.
Professional Investment Institutions Participate in This Round of Financing
This round of financing has attracted the participation of several investment institutions focusing on healthcare and technological innovation.
Rui enjoy yuan Fund
Rui enjoy yuan Fund is a professional equity investment institution focusing on the biomedical and health fields. Its investment areas mainly include innovative drugs, high-end medical equipment, and technology-based medical services.
Its investment portfolio includes healthcare companies such as Transcenta, Ascentage Pharma, Chipscreen Biosciences,鴻運華寧 (Hongyun Huaning), and Hygeia.
In this round of financing, Rui enjoy yuan Fund and Zhongnan Venture Capital Fund jointly served as lead investors.
Zhongnan Venture Capital Fund
Founded in 2008, Zhongnan Venture Capital Fund is a professional asset management institution focusing on technology fields such as biomedicine, semiconductors, and artificial intelligence.
Its healthcare investment cases include innovative drug companies such as EpimAb, Crown Bioscience, Drug Farm, Inmagene, Gene-Optimal, Yingli Pharma, CARsgen, Kintor, and Reistone.
Longpan Investment
Headquartered in Beijing, Longpan Investment has long focused on venture capital in the biopharmaceutical field.
Imbiorey received an 80 million RMB investment from Longpan Fund in its 2020 Pre-A round of financing.
Longpan Investment mainly focuses on innovative drugs and innovative medical devices, covering start-up, early-to-mid-stage, and growth-stage companies.
Longmen Capital
Longmen Capital focuses on early and growth-stage investments in the field of biomedical innovation.
Its investment direction covers innovative drugs and related healthcare companies, and it has a long-term focus on the industrialization of pharmaceutical technology achievements.
Zhongguancun Kaiyuan Capital
Zhongguancun Kaiyuan Capital was initiated and managed by Zhongguancun Venture Capital, focusing on early-stage venture capital in the fields of information technology and biomedicine.
From Early-Stage Financing to Clinical Stage: The Long-Term Capital Needs of Innovative Drug Companies
The development of innovative drug companies has obvious stages.
Companies need to continuously invest a large amount of funds and industrial resources from the establishment of technology platforms, discovery of drug candidates, to IND-enabling, clinical development, and commercialization.
Therefore, for innovative drug companies, financing is not a single event, but a continuous capital strategy in the process of enterprise development.
Imbiorey’s development path from the 80 million RMB Pre-A round financing in 2020 to the 230 million RMB Series A round financing in 2022 reflects the company’s continuous access to professional capital support at different R&D stages.
The cumulative financing amount for the two rounds reached:
310 million RMB
This round of financing further supports the company’s core cell therapy drug candidates to enter the clinical stage, and promotes the construction of capabilities such as GMP production facilities, talent, and external cooperation.
T-Capital’s Services in Healthcare Equity Financing
T-Capital is a consulting firm focusing on the broad healthcare field, providing:
- Equity Financing
- M&A
- Divestitures
- Licensing & Joint Ventures
- Cross-border Transactions
- Capital Strategy Consulting
In the Imbiorey project, T-Capital served as the financial advisor for two consecutive rounds of financing.
T-Capital has a long-term focus on healthcare companies with technological innovation or business model breakthroughs, with service areas covering:
- New drug R&D;
- Medical devices;
- Medical diagnostics;
- High-value consumables;
- Healthcare services;
- Emerging medical technologies;
- Biopharmaceuticals.
By connecting companies with capital, and domestic with international industrial resources, T-Capital helps healthcare companies find capital and strategic cooperation resources that match their development stage.
Why Do Healthcare Companies Need Professional Financial Advisors?
For innovative drug, medical device, and other healthcare companies, financing is not just about finding funds.
Companies also need to answer:
At What Stage Should a Company Raise Funds?
Financing too early may put pressure on valuation and equity structure; financing too late may affect R&D progress and strategic execution.
What Type of Investment Institutions Should Be Sought?
Different investment institutions have differences in investment stage, industrial resources, capital capacity, and subsequent support methods.
How to Clearly Explain the Company’s Technology and Business Value?
Innovative drug companies usually have high technical complexity. How to translate the technology platform, R&D pipeline, clinical value, market space, and team capabilities into an investment logic that investors can quickly understand is a very important part of the financing process.
How to Establish Long-Term Capital Relationships?
Innovative drug R&D cycles are long, and companies usually need multiple rounds of capital support.
Therefore, the job of a financing advisor should not be just to complete one round of financing, but to help the company establish a long-term connection with the capital market.
T-Capital Serves Healthcare Company Financing
If your company is undergoing Pre-A, Series A, Series B, or growth-stage financing, or is looking for industrial investors, strategic investors, and overseas capital, T-Capital can assist in formulating financing strategies and connecting with potential investment institutions based on the company’s development stage, financing needs, and industry characteristics.
We focus on serving:
Innovative Drugs | Biopharmaceuticals | Cell Therapy | Medical Devices | Medical Diagnostics | High-Value Consumables | Healthcare Services | Medical Technology
If your company is looking for capital, strategic partners, or the next round of financing opportunities, you are welcome to communicate with T-Capital.
Transaction Highlights
230 Million
Imbiorey’s 2022 Series A financing amount
310 Million
Cumulative financing amount for two rounds
2 Rounds
T-Capital served as financial advisor for two consecutive rounds
CAR-NK
Imbiorey’s core innovative cell therapy direction
2020 → 2022
Continuous financing services from Pre-A to Series A round
FAQ
What is the amount of Imbiorey’s Series A financing?
Imbiorey announced the completion of a 230 million RMB Series A financing on February 22, 2022.
Which institutions led Imbiorey’s Series A financing?
This round of financing was co-led by Rui enjoy yuan Fund and Zhongnan Venture Capital Fund, with participation from several investment institutions including Longmen Capital, Zhongguancun Kaiyuan Capital, Dongfang Huisheng, and Beiyu Bairui Fund.
Has Imbiorey completed financing before?
Yes. Imbiorey previously completed an 80 million RMB Pre-A round of financing in 2020. After the completion of the 2022 Series A round, the company’s cumulative financing amount reached 310 million RMB.
What role did T-Capital play in the Imbiorey project?
T-Capital served as the financial advisor for two consecutive rounds of financing for Imbiorey, including the 2020 Pre-A and 2022 Series A rounds.
What is Imbiorey’s main business?
Founded in 2014, Imbiorey is mainly engaged in R&D related to the treatment of tumors and immune diseases, and focuses on the development of innovative universal off-the-shelf CAR-NK and NK cell therapy drugs.
What is this round of financing mainly used for?
This round of financing is mainly used to advance core drug candidates such as IBR733 and IBR854 into the clinical stage, promote IND-enabling studies for multiple drug candidates, and support GMP plant construction, talent team building, external business cooperation, and company operations.
What kind of healthcare companies does T-Capital provide financing advisory services for?
T-Capital focuses on the broad healthcare field and provides consulting services such as equity financing, M&A, divestitures, licensing & joint ventures, and cross-border transactions for companies in fields such as new drug R&D, medical devices, medical diagnostics, high-value consumables, healthcare services, and emerging technologies.
When is a suitable time for a healthcare company to contact T-Capital?
If a company is planning its next round of financing, preparing to enter the clinical stage, needs to bring in strategic investors, or wants to find industrial partners and cross-border capital, it can communicate with T-Capital before the financing plan is finalized in order to formulate a corresponding capital strategy based on the company’s development stage.